azathioprine has been researched along with Uveitis, Posterior in 11 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Uveitis, Posterior: Inflammation of the choroid as well as the retina and vitreous body. Some form of visual disturbance is usually present. The most important characteristics of posterior uveitis are vitreous opacities, choroiditis, and chorioretinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ocular lesions, the main morbidity of Behcet's disease (BD), are the most difficult to treat." | 2.75 | Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). ( Akhlaghi, M; Chams-Davatchi, C; Davatchi, F; Faezi, T; Naderi, N; Nadji, A; Rezaipoor, M; Sadeghi-Abdollahi, B; Shahram, F; Shams, H, 2010) |
| "Retinal vasculitis was noted in majority of affected eyes and specifically arteritis was noticed in 32/57(56%)." | 1.51 | Ocular Manifestations and Visual Outcomes of Behçet's Uveitis in a Thai population. ( Kunavisarut, P; Pathanapitoon, K; Rothova, A; Saravuttikul, FA, 2019) |
| "Azathioprine was used at 2-3 mg/kg daily." | 1.40 | Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years. ( Akhlaghi, M; Ashofteh, F; Chams-Davatchi, C; Davatchi, F; Faezi, T; Ghodsi, Z; Mohtasham, N; Nadji, A; Sadeghi Abdollahi, B; Shahram, F; Shams, H, 2014) |
| "At the time of recurrence, four patients were on maintenance dose (5-10 mg/day) of oral corticosteroid while the remaining three were off treatment." | 1.35 | Posterior segment recurrences in Vogt-Koyanagi-Harada disease. ( Gupta, A; Gupta, V; Sachdev, N; Singh, R, 2008) |
| "To determine whether resolution of choroidal neovascularization (CNV), a recognized sight-threatening complication of endogenous posterior uveitis, and maintenance of vision could be achieved with immunosuppression." | 1.30 | Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. ( Arnold, JJ; Dees, C; Dick, AD; Forrester, JV, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohammadi, M | 1 |
| Shahram, F | 4 |
| Shams, H | 3 |
| Akhlaghi, M | 3 |
| Ashofteh, F | 2 |
| Davatchi, F | 4 |
| Pathanapitoon, K | 1 |
| Kunavisarut, P | 1 |
| Saravuttikul, FA | 1 |
| Rothova, A | 1 |
| Sadeghi Abdollahi, B | 1 |
| Nadji, A | 3 |
| Chams-Davatchi, C | 2 |
| Faezi, T | 2 |
| Ghodsi, Z | 1 |
| Mohtasham, N | 1 |
| Gattimallanahali, Y | 1 |
| Mangat, G | 1 |
| Canchi, B | 1 |
| Kakade, G | 1 |
| Rezaipoor, M | 1 |
| Sadeghi-Abdollahi, B | 1 |
| Naderi, N | 1 |
| Chams, H | 1 |
| Jamshidi, A | 1 |
| Akbarian, M | 1 |
| Gharibdoost, F | 1 |
| Sachdev, N | 1 |
| Gupta, V | 1 |
| Gupta, A | 1 |
| Singh, R | 1 |
| Krämer, M | 1 |
| Baumgärtel, MW | 1 |
| Neuen-Jacob, E | 1 |
| Berlit, P | 1 |
| Bentley, CR | 1 |
| Stanford, MR | 1 |
| Shilling, JS | 1 |
| Sanders, MD | 1 |
| Graham, EM | 1 |
| Dees, C | 1 |
| Arnold, JJ | 1 |
| Forrester, JV | 1 |
| Dick, AD | 1 |
| Lightman, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low-dose IL-2 Treatment on Behcet's Disease[NCT04065672] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-11-12 | Recruiting | ||
| A Double Blind Cross Over Clinical Trial to Determine Colchicine Efficacy in Behcet's Disease[NCT00700297] | Phase 2 | 169 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for azathioprine and Uveitis, Posterior
| Article | Year |
|---|---|
High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study.
Topics: Administration, Intravenous; Adult; Azathioprine; Behcet Syndrome; Cyclophosphamide; Double-Blind Me | 2017 |
Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Behcet Syndrome; Cyclophosp | 2010 |
Azathioprine and low dose pulse cyclophosphamide in severe ocular lesions of Behçet's disease. A preliminary report.
Topics: Azathioprine; Behcet Syndrome; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combina | 2003 |
8 other studies available for azathioprine and Uveitis, Posterior
| Article | Year |
|---|---|
Ocular Manifestations and Visual Outcomes of Behçet's Uveitis in a Thai population.
Topics: Adolescent; Adult; Age of Onset; Azathioprine; Behcet Syndrome; Child; Drug Therapy, Combination; Fe | 2019 |
Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years.
Topics: Azathioprine; Behcet Syndrome; Cyclophosphamide; Drug Resistance; Drug Therapy, Combination; Humans; | 2014 |
Behçet's syndrome with gangrenous bilateral lower limbs.
Topics: Adult; Amputation, Surgical; Anti-Inflammatory Agents; Azathioprine; Behcet Syndrome; Female; Gangre | 2016 |
Posterior segment recurrences in Vogt-Koyanagi-Harada disease.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Fluorescein Angiography; Glucocorticoids; Hu | 2008 |
[Myalgia in Neuro-Behçet's disease. Medication side effects or expression of underlying disease].
Topics: Adult; Azathioprine; Behcet Syndrome; Biopsy; Brain Diseases; Cyclosporine; Dose-Response Relationsh | 2008 |
Macular ischaemia in posterior uveitis.
Topics: Adult; Azathioprine; Cyclosporine; Female; Fluorescein Angiography; Humans; Immunosuppressive Agents | 1993 |
Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis.
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Choroidal Neovascularization; Cyclosporine | 1998 |
Use of steroids and immunosuppressive drugs in the management of posterior uveitis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Azathioprine; Chlorambucil; Cyclophosphamide; Cyclosp | 1991 |